Korro Bio opened lower at $14.23, compared with its previous close of $14.41. In the last trading session, the stock traded between $13.77 and $14.67. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Korro Bio is now worth
$ 91.99
Resulting in a loss of
$ 8.01 (8.01%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
80%
Hold
20%
Sell
0%
Markets Today
Today's Change
$-0.17 (-1.18%)
Day High
$14.67
Day Low
$13.77
Day Open
$14.23
Prev Close
$14.41
Volume
1,68,032
1W Return
-13.98%
1M Return
52.33%
3M Return
6.28%
6M Return
24.26%
1Y Return
-56.59%
Fundamentals
Market Cap ($ Mn)
195
PE Ratio
-
PB Ratio
1.84
PEG Ratio
-
ROE
-103.78%
ROCE
-71.78%
EPS (TTM)
-
Investment Returns
1 Week
-13.98%
1 Month
52.33%
3 Months
6.28%
6 Months
24.26%
9 Months
15.87%
Financials
Quarterly
All values in $ Mn
2.5
Mar 25
1.5
Jun 25
1.1
Sep 25
1.3
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
17Oct
Korro Bio grants 4,000 stock options to new hires at $8.88
Korro Bio granted 4,000 non-statutory stock options to two new employees. Exercise price set at $8.88 per share based on October 14, 2026 closing price. Grants comply with Nasdaq Listing Rule 5635(c)(4) for inducement awards. Options vest over four years with 25% cliff and monthly installments thereafter.
27 days ago
6Oct
Korro Bio doses first cohort in Phase 1/2 ANCHOR trial for KRRO-121
Korro Bio dosed the first cohort of healthy volunteers with a single 2mg/kg dose of KRRO-121. The ANCHOR trial includes Phase 1 safety studies in up to 50 healthy volunteers. Dosing for UCD patients is expected to begin in the first half of 2027. Interim clinical readout for the Phase 2 component is expected in the second half of 2027.
1mo ago
12Sep
Korro Bio grants 5,000 stock options to three new hires at $12.93
Korro Bio granted 5,000 non-statutory stock options to three new hires. Exercise price set at $12.93 per share, matching closing price on Sept 9, 2026. Options vest over four years with a 25% cliff after the first anniversary. Grants approved under 2026 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
2mo ago
27Aug
Korro Bio CEO to speak at Citi, Cantor biopharma conferences
Korro Bio CEO Ram Aiyar to speak at Citi and Cantor biopharma conferences. Citi fireside chat scheduled for September 9, 2026, at 8:40 am ET. Cantor fireside chat set for September 10, 2026, at 1:00 pm ET. Company leverages OPERA platform for RNA-editing genetic medicines.
2mo ago
11Jul
Korro Bio grants inducement stock options to new hires
Korro Bio granted non-statutory stock options to seven newly hired employees as an employment inducement, covering an aggregate of 23,000 shares. The options have exercise prices of $10.59 and $14.72 per share, based on Nasdaq closing prices on June 10, 2026, and July 8, 2026, respectively. The grants were approved by the independent Compensation Committee under the 2026 Inducement Plan and vest over four years.
